vs
GENMAB A/S（GMAB）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
越洋钻探的季度营收约是GENMAB A/S的1.1倍（$1.0B vs $925.0M），GENMAB A/S净利率更高（36.3% vs 2.4%，领先33.9%），GENMAB A/S同比增速更快（18.7% vs 9.6%），GENMAB A/S自由现金流更多（$327.0M vs $321.0M）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
GMAB vs RIG — 直观对比
营收规模更大
RIG
是对方的1.1倍
$925.0M
营收增速更快
GMAB
高出9.2%
9.6%
净利率更高
GMAB
高出33.9%
2.4%
自由现金流更多
GMAB
多$6.0M
$321.0M
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $1.0B |
| 净利润 | $336.0M | $25.0M |
| 毛利率 | 93.8% | 42.0% |
| 营业利润率 | 38.9% | 23.0% |
| 净利率 | 36.3% | 2.4% |
| 营收同比 | 18.7% | 9.6% |
| 净利润同比 | 65.5% | 257.1% |
| 每股收益（稀释后） | $5.42 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABRIG
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | $925.0M | $988.0M | ||
| Q1 25 | — | $906.0M | ||
| Q4 24 | — | $952.0M | ||
| Q3 24 | — | $948.0M | ||
| Q2 24 | $779.0M | $861.0M | ||
| Q1 24 | — | $763.0M |
净利润GMABRIG
| Q4 25 | — | $25.0M | ||
| Q3 25 | — | $-1.9B | ||
| Q2 25 | $336.0M | $-938.0M | ||
| Q1 25 | — | $-79.0M | ||
| Q4 24 | — | $7.0M | ||
| Q3 24 | — | $-494.0M | ||
| Q2 24 | $203.0M | $-123.0M | ||
| Q1 24 | — | $98.0M |
毛利率GMABRIG
| Q4 25 | — | 42.0% | ||
| Q3 25 | — | 43.2% | ||
| Q2 25 | 93.8% | 39.4% | ||
| Q1 25 | — | 31.8% | ||
| Q4 24 | — | 39.2% | ||
| Q3 24 | — | 40.6% | ||
| Q2 24 | 96.4% | 38.0% | ||
| Q1 24 | — | 31.5% |
营业利润率GMABRIG
| Q4 25 | — | 23.0% | ||
| Q3 25 | — | -163.1% | ||
| Q2 25 | 38.9% | -97.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | — | 13.7% | ||
| Q3 24 | — | -51.2% | ||
| Q2 24 | 30.3% | -6.9% | ||
| Q1 24 | — | -0.4% |
净利率GMABRIG
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | -187.1% | ||
| Q2 25 | 36.3% | -94.9% | ||
| Q1 25 | — | -8.7% | ||
| Q4 24 | — | 0.7% | ||
| Q3 24 | — | -52.1% | ||
| Q2 24 | 26.1% | -14.3% | ||
| Q1 24 | — | 12.8% |
每股收益（稀释后）GMABRIG
| Q4 25 | — | $0.13 | ||
| Q3 25 | — | $-2.00 | ||
| Q2 25 | $5.42 | $-1.06 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | — | $-0.14 | ||
| Q3 24 | — | $-0.58 | ||
| Q2 24 | $3.13 | $-0.15 | ||
| Q1 24 | — | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $620.0M |
| 总债务越低越好 | — | $5.2B |
| 股东权益账面价值 | $5.3B | $8.1B |
| 总资产 | $6.5B | $15.6B |
| 负债/权益比越低杠杆越低 | — | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资GMABRIG
| Q4 25 | — | $620.0M | ||
| Q3 25 | — | $833.0M | ||
| Q2 25 | $1.3B | $377.0M | ||
| Q1 25 | — | $263.0M | ||
| Q4 24 | — | $560.0M | ||
| Q3 24 | — | $435.0M | ||
| Q2 24 | $622.0M | $475.0M | ||
| Q1 24 | — | $446.0M |
总债务GMABRIG
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.9B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $6.2B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $6.8B |
股东权益GMABRIG
| Q4 25 | — | $8.1B | ||
| Q3 25 | — | $8.1B | ||
| Q2 25 | $5.3B | $9.4B | ||
| Q1 25 | — | $10.2B | ||
| Q4 24 | — | $10.3B | ||
| Q3 24 | — | $10.2B | ||
| Q2 24 | $4.4B | $10.7B | ||
| Q1 24 | — | $10.5B |
总资产GMABRIG
| Q4 25 | — | $15.6B | ||
| Q3 25 | — | $16.2B | ||
| Q2 25 | $6.5B | $17.8B | ||
| Q1 25 | — | $19.0B | ||
| Q4 24 | — | $19.4B | ||
| Q3 24 | — | $19.5B | ||
| Q2 24 | $5.6B | $20.3B | ||
| Q1 24 | — | $19.9B |
负债/权益比GMABRIG
| Q4 25 | — | 0.64× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | $321.0M |
| 自由现金流率自由现金流/营收 | 35.4% | 30.8% |
| 资本支出强度资本支出/营收 | 2.4% | 2.7% |
| 现金转化率经营现金流/净利润 | 1.04× | 13.96× |
| 过去12个月自由现金流最近4个季度 | — | $626.0M |
8季度趋势，按日历期对齐
经营现金流GMABRIG
| Q4 25 | — | $349.0M | ||
| Q3 25 | — | $246.0M | ||
| Q2 25 | $349.0M | $128.0M | ||
| Q1 25 | — | $26.0M | ||
| Q4 24 | — | $206.0M | ||
| Q3 24 | — | $194.0M | ||
| Q2 24 | $438.0M | $133.0M | ||
| Q1 24 | — | $-86.0M |
自由现金流GMABRIG
| Q4 25 | — | $321.0M | ||
| Q3 25 | — | $235.0M | ||
| Q2 25 | $327.0M | $104.0M | ||
| Q1 25 | — | $-34.0M | ||
| Q4 24 | — | $177.0M | ||
| Q3 24 | — | $136.0M | ||
| Q2 24 | $430.0M | $49.0M | ||
| Q1 24 | — | $-169.0M |
自由现金流率GMABRIG
| Q4 25 | — | 30.8% | ||
| Q3 25 | — | 22.9% | ||
| Q2 25 | 35.4% | 10.5% | ||
| Q1 25 | — | -3.8% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | — | 14.3% | ||
| Q2 24 | 55.2% | 5.7% | ||
| Q1 24 | — | -22.1% |
资本支出强度GMABRIG
| Q4 25 | — | 2.7% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | 2.4% | 2.4% | ||
| Q1 25 | — | 6.6% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | 1.0% | 9.8% | ||
| Q1 24 | — | 10.9% |
现金转化率GMABRIG
| Q4 25 | — | 13.96× | ||
| Q3 25 | — | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 29.43× | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | — | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
